MenaQ7 contains one of the most bio-available forms of natural vitamin K2, known as menaquinone-7. It’s extracted from Natto, a fermented soy food that has been consumed in Japan for hundreds of years.
“MenaQ7 complements our portfolio of health ingredients and fits well with our strategic focus on Health and Nutrition,” said Fabienne Saadane-Oaks, President of Danisco BioActives. “The agreement will contribute to strengthening our range of products for cardiovascular health in addition to opening a new platform for bone health.”
“The agreement represents a major commercial breakthrough for NattoPharma,” said Thomas Christensen, President and CEO of NattoPharma, a Norway-based company and exclusive supplier of MenaQ7. “Danisco is one of the world’s leading suppliers of food ingredients, and our partnership will allow for high-volume production and supply of our unique product to the fast-growing food fortification industry.”
The agreement doesn’t cover distribution in Norway, where NattoPharma will market the product directly to food manufacturers. The parties have agreed not to disclose any details of the agreement.
© FoodBev Media Ltd 2020
World Beverage Innovation Awards – NOW OPEN FOR ENTRIES!
The awards celebrate excellence and innovation across the global beverage industry.
Don’t miss out on having your innovations recognised on a global scale.
Early bird deadline 11 June – enter now!